Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: Analysis of remission induction and stem cell mobilization

References

• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, Neser S, Al-Ali K H, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986–1992
   PubMed Web of Science ®Google Scholar
• Maloney D G, Grillo-Lopez A J, White C A, Bodkin D, Schilder R J, Neidhart J A, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Gianni A M, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
   PubMed Web of Science ®Google Scholar
• Shipp M A, Abeloff M D, Antman K H, Carroll G, Hagenbeek A, Loeffler M, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429
   PubMed Web of Science ®Google Scholar
• Marcus R. Current treatment options in aggressive lymphoma. Leuk Lymphoma 2003; 44(Suppl 4)S15–S27
   PubMed Web of Science ®Google Scholar
• Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, et al. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma 2006; 47: 1545–1552
   PubMed Web of Science ®Google Scholar
• Bierman P J, Vose J M, Anderson J R, Bishop M R, Kessinger A, Armitage J O. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445–450
   PubMed Web of Science ®Google Scholar
• Freedman A S, Neuberg D, Mauch P, Soiffer R J, Anderson K C, Fisher D C, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333
   PubMed Web of Science ®Google Scholar
• Apostolidis J, Gupta R K, Grenzelias D, Johnson P W, Pappa V I, Summers K E, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527–536
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Barbieri E, Visani G, Gherlinzoni F, Perini F, Neri S, et al. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica 1994; 79: 508–512
   PubMed Web of Science ®Google Scholar
• Velasquez W S, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Bertino J R, Glassman J R, Hedrick E E, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785
   PubMed Web of Science ®Google Scholar
• Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794
   PubMed Web of Science ®Google Scholar
• Micallef I N, Apostolidis J, Rohatiner A Z, Wiggins C, Crawley C R, Foran J M, et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000; 1: 367–373
   PubMedGoogle Scholar
• Sugrue M W, Williams K, Pollock B H, Khan S, Peracha S, Wingard J R, Moreb J S. Characterization and outcome of “hard to mobilize” lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000; 39: 509–519
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Hedrick E E, Donnelly G B, Hunte S, Priovolos A C, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000; 96: 2399–2404
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667–2674
   PubMed Web of Science ®Google Scholar
• Gopal A K, Gooley T A, Maloney D G, Petersdorf S H, Eary J F, Rajendran J G, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102: 2351–2357
   PubMed Web of Science ®Google Scholar
• Clavio M, Garrone A, Pierri I, Michelis G L, Balocco M, Albarello A, et al. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. Oncol Rep 2005; 14: 933–940
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Tani M, Molinari A L, Stefoni V, Zuffa E, Alinari L, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002; 87: 816–821
   PubMed Web of Science ®Google Scholar
• Pocali B, De Simone M, Annunziata M, Palmieri S, D'Amico M R, Copia C, et al. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2004; 45: 1605–1609
   PubMed Web of Science ®Google Scholar
• Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006; 17(Suppl 4)iv31–iv32
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Staak O, Glossmann J P, Reineke T, Scheuss H, Diehl V, et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol 2007; 86: 107–115
   PubMed Web of Science ®Google Scholar
• Vose J, Sneller V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann Oncol 2003; 14(Suppl 1)i17–i20
   PubMed Web of Science ®Google Scholar
• Mey U J, Olivieri A, Orlopp K S, Rabe C, Strehl J W, Gorschlueter M, et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma 2006; 47: 2558–2566
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Leppa S, Kvaloy S, Holte H. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma – the Nordic Lymphoma Group experience. Eur J Haematol 2004; 73: 179–182
   PubMed Web of Science ®Google Scholar
• Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen H E, Canizo C D, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93: 405–412
   PubMed Web of Science ®Google Scholar
• Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285–290
   PubMed Web of Science ®Google Scholar
• Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004; 72: 10–17
   PubMed Web of Science ®Google Scholar
• Bishton M J, Lush R J, Byrne J L, Russell N H, Shaw B E, Haynes A P. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007; 136: 752–761
   PubMed Web of Science ®Google Scholar
• Nickenig C, Dreyling M, Hoster E, Ludwig W D, Dorken B, Freund M, et al. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas – results of a randomized comparison by the German Low-Grade Lymphoma Study Group. Ann Oncol 2007; 18: 136–142
   PubMed Web of Science ®Google Scholar